AU2012216500B2 - Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus - Google Patents

Abstract

Abstract Phosphoramidate derivatives of nucleoside compounds derived from bases such as adenine and 5 guanine have enhanced therapeutic potency, in particular, enhanced potency with respect to the prophylaxis or treatment of a viral infection such as hepatitis C virus. The glycoside moiety of the nucleoside compound is suitably substituted at the p-2' position with methyl and the phosphoramidate group suitably comprises 1-naphthyl linked by -0- to the P atom. SPEC-85393

Description

AUSTRALIA Patents Act COMPLETE SPECIFICATION (ORIGINAL) Class Int. Class Application Number: Lodged: Complete Specification Lodged: Accepted: Published: Priority Related Art: Name of Applicant: University College Cardiff Consultants Limited and Katholieke Universiteit Leuven Actual Inventor(s): Christopher McGuigan, Plinio Perrone, Johan Neyts Address for Service and Correspondence: PHILLIPS ORMONDE FITZPATRICK Patent and Trade Mark Attorneys 367 Collins Street Melbourne 3000 AUSTRALIA Invention Title: NUCLEOSIDE ARYL PHOSPHORAMIDATES AND THEIR USE AS ANTI-VIRAL AGENTS FOR THE TREATMENT OF HEPATITIS C VIRUS Our Ref: 949383 POF Code: 967/280345, 492923 The following statement is a full description of this invention, including the best method of performing it known to applicant(s): soowg la The present application is a divisional application from Australian patent application number 2007323220. The entire disclosure of which is incorporated herein by reference. 5 Chemical Compounds The present invention relates to chemical compounds, their preparation and their use in the treatment and prophylaxis of viral infections, particularly in homo sapiens. Particularly, although not exclusively, the present invention relates to chemical compounds useful as 10 antiviral agents active with respect to hepatitis C virus (HCV). WO 2006/012078 A describes certain nucleoside aryl phosphoramidates, their synthesis, and their use as precursors to inhibitors of RNA-dependent RNA viral polymerase, particularly their use as precursors to inhibitors of hepatitis C virus (HCV) NS5B 15 polymerase, as precursors to inhibitors of HCV replication, and for the treatment of hepatitis C infection. WO 2006/100439 A relates to phosphoramidates of cladribine, isocladribine, fludaribine and clofarbine and their use in the treatment of a cancer such as leukaemia. 20 The intracellular kinase-mediated activation of the compounds described in WO 2006/100439 A with respect to their treatment of cancer is different to the intracellular kinase-mediated activation required in the treatment and prophylaxis of viral infections. 25 It is an aspect of the present invention to provide novel chemical compounds that provide improved prophylaxis and treatment of viral infections in homo sapiens, in particular improved prophylaxis and treatment of hepatitis C infection in homo sapiens. According to a first aspect of the present invention there is provided a compound of 30 formula I: C : wrDocumenti dox WO 2008/062206 PCT/GB2007/004480 2 x >-Z Y N 0 Ar-0-P-0 I Q RZN

CH

2 T R,4

R

2 OT" V Rg-0 0 wherein: 5 Ar comprises two or more fused aromatic rings and is selected from the group consisting of C9.30aryl and C 6

-

3 oheteroaryl, any of which rings are optionally substituted; T is selected from the group consisting of hydrogen (-H), fluoro (-F), azido (-N 3 ), amino (

NH

2 ), hydroxy (-OH), CI.

3 alkyl (C.3-), Ci.

3 alkoxy (Cs.30-), mercapto (-SH) and C 1 . 10 3 alkylthio (C 1

.

3 S-); V is selected from the group consisting of -OT', hydrogen (-H), fluoro (-F) and chloro ( Cl), where T' is selected from the group consisting of hydrogen (-H), methyl (-CH 3 ), C1. i 6 alkylcarbonyl (CI-- 16 alkyl-C(=0)-), C 2 -.salkenylcarbonyl (C 2 -salkenyl-C(=0)-), C1. 15 oalkoxycarbonyl (C.joalkyl-0-C(=0)-), C 3 .6cycloalkylcarbonyl (C 3

.

6 cycloalkyl-C(0)-) and C 3 -scycloalkyloxycarbonyl (C 3

.

4 cycloalkyl-0-C(=O)-); T" is selected from the group consisting of hydrogen (-H), methyl (-CH 3 ), C1. 1 6 alkylcarbonyl (CI- 16 alkyl-C(=0)-), C 2

.

18 alkenylcarbonyl (C 2 .Isakenyl-C(=0)-), Ci. 20 ioalkoxycarbonyl (C 1 .. oalkyl-O-C(=0)-), C 3

-

4 cycloalkylcarbonyl (C 3

.

6 cycloalkyl-C(=0)-) and C3.6cycloalkyloxycarbonyl (C 3 .6cycloakyl--C(=0)-); n is 0 or 1, wherein when n is 1, X is =0, and WO 2008/062206 PCT/GB2007/004480 3 when n is 0, a double bond exists between position 3 and position 4 and X is selected from the group consisting of H, OH, F, Cl, Br, I, C 1

.

6 alkyl and NR 5 R, where each of R5 and R 6 is independently selected from H and C 1 ., alkyl; 5 Z is selected from the group consisting of H, OH, F, Cl, Br, I, C 1

.

6 alkyl and NR 5

R

6 , where each of R 5 and & is independently selected from H and C.

6 alkyl; Y is selected from the group consisting of H, OH, F, Cl, Br, I, C 1 akyl, C 2 .salkynyl and NRSR, where each of R 5 and & is independently selected from H and C1.

6 alkyl; 10 Q is selected from the group consisting of 0, S and CR 7 Rs, where R7 and R are independently selected from H and C 1 .-alkyl; each of Al and R 2 is independently selected from H, and the group consisting of CI-2oalkyl, 15 C 2

.

2 oalkenyl, CI-20alkoxy, CI- 20 alkoxyCI-2oalkyl, CI-2oalkoxyC6- 3 0aryl, C2- 2 oalkynyl, C3 20cycloalkylC6-30aryl, Cs30aryloxy, C 5

.

2 oheterocyclyl, any of which is optionally substituted; and each of R 3 and R 4 is independently selected from H, and the group consisting of Ci- 2 oalkyl, 20 C 2

.

2 oalkenyl, C 1

.

2 oalkoxy, CI-2oalkoxyCI.

2 oalkyl, CI-20alkoxyC-30aryl, C 2 .20alkynyl, C 3 . 20 cycloalkylC& 3 oaryl, C6-30aryloxy, Cs- 2 oheterocyclyl, any of which is optionally substituted, preferably R 3 is alkyl, more preferably R 3 is selected from the group consisting of methyl, ethyl, 2-propyl, n-propyl, cyclohexyl, 2-butyl and benzyl; 25 with the proviso that R, and R 4 can together comprise a -(CH 2

)

3 - alkylene chain; and pharmaceutically acceptable salts, solvates and prodrugs thereof According to a further aspect of the present invention there is provided a compound of 30 formula I for use in a method of treatment, suitably in the prophylaxis or treatment of a viral infection, more suitably in the prophylaxis or treatment of hepatitis C virus.

3a According to a further aspect of the present invention there is provided a compound according to Formula II: X H-0-P-O I Q R-

CH

2 T OT" V R-OQO 5 where: T is selected from the group consisting of hydrogen (H-), fluoro (F-), azido (N 3 -), amino(- NH 2 ), hydroxy (-OH), CI.

3 alkyl (Ci.

3 -), C 1

.

3 alkoxy (C 1

.

3 alkyl-O-), mercapto (-SH) and C 1

.

3 alkylthio (C 1

.

3 alkylS-); 10 V is selected from the group consisting of -OT', hydrogen (-H), fluoro (-F) and chloro (-Cl), where T' is selected from the group consisting of hydrogen (-H), methyl (-CH3),

C

1

.

1 6 alkylcarbonyl (C 1

-

16 alkyl-C(=O)-), C 2

-

18 alkenylcarbonyl (C 2

-

1 salkenyl-(=0)-),

C

1 .oalkoxycarbonyl (C 1 .- oalkyl-O-C(=O)-), C 3

.

6 cycloalkylcarbonyl (C 3

.

6 cycloalkyl-C(=O)-) 15 and C 3

.

6 cycloalkyloxycarbonyl (C 3

.

6 cycloalkyl-O-C(=O)-); T" is selected from the group consisting of hydrogen (-H), methyl (-CH 3 ), C 1 .i 6 alkylcarbonyl

(CI-

1 6 alkyl-C(=O)-), C 2

.

1 salkenylcarbonyl (C 2 -salkenyl-C(=O)-), CI- 1 oalkyloxycarbonyl (Ci.ioalkyl-O-C(=O)-), C 3

.

6 cycloalkylcarbonyl (C 3

-

6 cycloalkyl 20 C(=O)-) and C 3

.

6 cyc 1 oalkyloxycarbonyl (C 3

.

6 cycloalkyl-O-C(=O)-); n is 0 or 1, wherein when n is 1, X is =0, and when n is 0, a double bond exists between position 3 and position 4 and X is 25 selected from the group consisting of H, OH, F, Cl, Br, I, CI.

6 alkyl and NR 5

R

6 , where each of R 5 and R 6 is independently selected from H and CI.

6 alkyl; C:%pa Do cun Wt1.docx 3b Z is selected from the group consisting of H, OH, F, Cl Br, I, C 1

.

6 alkyl and NR 5

R

6 , where each of R 5 and R( is independently selected from H and CI.

6 alkyl; 5 Y is selected from the group consisting of H, OH, F, Cl, Br, I, C 1

.

6 alkyl, C 2 -salkynyl,

NR

5

R

6 , where each of R 5 and R 6 is independently selected from H and C 1

.

6 alkyl; Q is selected from the group consisting of 0, S and CR 7 Rs, where R 7 and R are independently selected from H and Ci- 6 alkyl; 10 each of R 1 and R 2 is independently selected from H, and the group consisting of C 1

-

2 oalkyl, C 2

.

2 oalkenyl, CI-20alkoxy, C 1 -2oalkoxyCI.

2 0alkyl, C 1 -2oalkoxyC 6

.

3 oaryl, C 2

.

2 oalkynyl, C 3 -20cycloalkylC 6 -30aryl, C 6

.

3 0aryloxy and C5-20heterocyclyl; 15 each of R 3 and R 4 is independently selected from H, and the group consisting of C 1 . 20alkyl, C 2 -20alkenyl, CI.20alkoxy, Ci-20alkoxyCI-20alkyl, Ci-20alkoxyC 6

.

3 0aryl, C 2 2 oalkynyl, C 3 -20cycloalkylC 6 .30aryl, C 6 .30aryloxy and C 5 -20heterocyclyl; with the proviso that R, and R 4 can together comprise a -(CH 2

)

3 -alkylene chain; 20 wherein alkyl is a straight or branched saturated monovalent cyclic or acyclic hydrocarbon radical, alkenyl is a straight or branched unsaturated monovalent acyclic or cyclic hydrocarbon radical having one or more C=C double bonds and alkynyl is a straight or branched unsaturated monovalent acyclic or cyclic hydrocarbon radical 25 having one more triple C-C bonds; and wherein alkyl, alkenyl or alkynyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of hydroxy, acyl, acyloxy, nitro, amino, amido, -SO 3 , -H, -SH, and -SR' wherein R' is independently selected from R 1 , 30 carboxyl, CI.

6 esters, CI.

6 aldehyde, cyano, CI.

6 alkylamino, C 1

.

6 dialkylamino, thiol, chloro, bromo, fluoro, iodo, C 5

.

7 cycloalkyl, C 5

.

7 cycloalkenyl, C 5 .-cycloalkynyl, C 5 . Iaryl, Cs. 1 arylC 1

.

6 alkyl and C 5

-

2 oheterocyclyl; and pharmaceutically acceptable salts, and solvates thereof. 35 WO 2008/062206 PCT/GB2007/004480 4 According to a further aspect of the present invention there is provided the use of a compound of formula I in the manufacture of a medicament for the prophylaxis or treatment of a viral infection, preferably a medicament for the prophylaxis or treatment of hepatitis C virus. 5 According to a further aspect of the present invention, there is provided a method of prophylaxis or treatment of a viral infection, particularly hepatitis C virus, comprising administration to a patient, suitably a homo sapiens, in need of such treatment an effective dose of a compound of formula I. 10 According to a further aspect of the present invention, there is provided a pharmaceutical composition comprising a compound of formula I in combination with a pharmaceutically acceptable carrier, diluent or excipient. 15 According to a further aspect of the present invention there is provided a method of preparing a pharmaceutical composition comprising the step of combining a compound of formula I with a pharmaceutically acceptable excipient, carrier or diluent. According to a further aspect of the present invention there is provided a process for the 20 preparation of a compound of formula I, the process comprising reacting a compound of formula III: X N HO

CH

2 T OT" V 25 WO 2008/062206 PCT/GB2007/004480 5 with a compound of formula IV: i R 0 Ri-0-_C N-P-Cl R2 Y Ar where Ar, T, V, T", n, X, Y, Z, Q, RI, R 2 , R 3 and R 4 have the meanings set out above with respect to Formula I. 5 It is to be understood that the present invention extends to metabolic intermediates of compounds of formula I, wherein Ar is H and R3 is H or R 3 is as defined above. It is appreciated that having regard to the compounds defined above with respect to 10 Formulae I and III, a compound where n is 1 and X is =0 is the keto tautomeric form of an otherwise equivalent enol compound where n is 0 and X is OH. The present invention particularly includes guanine as the base moiety where n is 1, X is =0, Y is NH 2 and no double bond exists between position 3 and position 4 i.e. between the 15 carbon ring atom bearing the =0 and the adjacent ring nitrogen atom. Compounds embodying the present invention have surprisingly been found to have enhanced anti-viral activity. In particular, compounds embodying the present invention have been found to have enhanced potency with respect to hepatitis C virus. 20 The enhanced anti-viral potency of the compounds of the present invention is believed to be due to the presence in the molecule of formula I of the combination of the fused multi ring entity for Ar in the phosphoramidate moiety and the methylene (-CH 2 -) group at the p 2' position in the glycoside moiety of the nucleoside, with T, V and T" as set out above. 25 By C9.

3 0aryl is meant an aromatic entity comprising 9 to 30 ring carbon atoms in an aryl format. By C6 30 heteroaryl is meant an aromatic entity comprising 6 to 30 ring carbon atoms in an aryl format, with at least one aryl ring containing a ring hetero atom.

WO 2008/062206 PCT/GB2007/004480 6 Suitably, Ar can comprise two, three, four, five or six fused aromatic rings. Preferably, Ar comprises an aryl entity in the form of two or three fused aromatic rings. More preferably, Ar is a two-ring fused aromatic entity selected from C 9 to C 20 aryl and C 6 to C 20 heteroaryl. Where Ar is heteroaryl, suitably 1 to 12 hetero atoms are within the aryl rings and suitably 5 are selected, independently, from 1 to 4 nitrogen atoms, 1 to 4 oxygen atoms and 1 to 4 sulphur atoms. Preferably, the hetero atoms include nitrogen. Available carbon atoms and/or heteroatoms in the aryl or heteroaryl ring system of Ar may be substituted on the ring with one or more substituents, as set out below with respect to 10 the substituents that may be present on the group Ar. Preferably Ar is unsubstituted. Suitably, Ar is naphthyl (CloH 7 ) or quinolyl (C 9

H

6 N), each of which may be optionally substituted. 15 Most suitably, Ar is naphthyl. The naphthyl entity is preferably linked to the O-P entity at the 1 or a position on the naphthyl group, i.e. at a C atom adjacent the fused bond between the two rings in the naphthyl group. Any optional substituent is preferably present at the 4 position. Preferably Ar is unsubstituted 1-naphthyl. 20 When Ar is quinolyl, it is preferably linked to the O-P entity at the 4 position on the quinolyl group, i.e. on the same ring as that containing the hetero atom N, which N is numbered as position 1. Any substituent present is preferably present at the 6 position, i.e on the ring not containing the hetereo N atom, which N is numbered as position 1. 25 Preferably T is selected from the group consisting of hydrogen (H-), fluoro (F-), methyl (CHr) and ethyl (C 2 H-). Preferably V is selected from the group consisting of hydrogen (H-), fluoro (F-) and OT', where T' is hydrogen (H-) or methyl (CH 3 -). 30 Preferably T" is hydrogen (H-). A preferred combination of T, V and r' is T = H, V = OH and T"= H.

WO 2008/062206 PCT/GB2007/004480 7 The combination of the above recited preferred entities for Ar with T = H, V = OH and T" = H is especially preferred. 5 Preferably n is I and X is =0. More preferably n is 1, X is =0 and Y is NH2 and the nucleoside base moiety corresponds to 9-linked guanine. Where Z is H, the nucleoside base moiety corresponds to unsubstituted 9-linked guanine. Where Z is not H, the nucleoside base moiety corresponds to 8-substituted 9-linked guanine. 10 Alternatively, preferably n is 0 and X is selected from the group consisting of NH 2 , F, Cl and NRSR 6 where one of R 5 and R 6 is H and one of R 5 and R6 is C1. 6alkyl. Where n is 0, X is NH 2 , Y is H and Z is H, the nucleoside base moiety corresponds to 9-linked adenine. Preferably, Y is selected from the group consisting of H, F, Cl, NH 2 and NR 5

R

6 where one 15 of Rs and R 6 is H and one of R 5 and R 6 is CI-salkyl. Preferably, Z is selected from the group consisting of H, F and Cl. Preferably, Q is 0. 20 Preferably, R 3 is alkyl. More preferably, R 3 is selected from the group consisting of methyl

(-CH

3 ), ethyl (CH 3

CH

2 -), 2-propyl ((CH 3

)

2 CH-), n-propyl (CH 3

-CH

2

-CH

2 -), cyclohexyl (C61H11-), 2-butyl ((CH 3

)C(H)(CH

2

CH

3 )-) and benzyl (C6H5CH2-), even more preferably R 3 is selected from the group consisting of methyl, ethyl, 2-propyl and benzyl, even more 25 preferably R 3 is selected from the group consisting of ethyl and benzyl. Preferably, R 4 is H or, together with RI, comprises (-(CH 2

)

3 -) so as to provide a group corresponding to proline. 30 Preferably, RI and R 2 are independently selected from the group consisting of H, 2-propyl

((CH

3

)

2 CH-), benzyl (C6H5CH2-) and -CH 2 isopropyl ((CH 3

)

2

C(H)-CH

2 -) or are selected such that they correspond to the side chains of a natural amino acid.

WO 2008/062206 PCT/GB2007/004480 8 Preferably, one of R, and R 2 is methyl (-CH 3 ) and one of R, and R 2 is H, such that the C atom bearing R, and R 2 has chirality L as in natural alanine. Preferred compounds have in combination the preferred identities for Ar, T, V, T', T", X, 5 Y, Z, Q, RI, R 2 , R 3 and R 4 as set out above. Particularly preferred compounds have: n= ,X==O, Y=NH 2 , Z= H, Q= O,T=H, V= OHand T"=H and arethus derived 10 from guanine; and n=, X=NH 2 , Y- Z= H, Q= 0, T= H,nV = OH andT=H and arethus derivedfrom adenine. 15 Each of the particularly preferred compounds set out immediately above and so derived from guanine or adenine is especially preferred when each of Ar, R 1 , R 2 , R 3 and R4 has the preferred identities set out above, and is especially preferred when Ar is I -naphthyl and R 3 is benzyl or ethyl. 20 Particularly preferred compounds are described in Examples 2, 3, 4, 6, 7, 8 and 11 and set out in Table II below. The phosphorus centre in compounds of formula I may be one diastereoisomer Re or Sp or it may be a mixture of the diastereoisomers Rp or Sp. Preferably it is one pure 25 diastereoisomer. Suitably the more active diastereoisomer is selected. Suitably the pharmaceutical acceptable salts, solvates and prodrugs of compounds of formula I are esters or amides at the 3'-OH of the glycoside moiety of the nucleoside group. 30 Preferably the process for preparing the compound of formula I includes the step of protecting free OH groups, other than 5' on the glycoside moiety of the nucleoside group. The phosphorochloridate may be prepared from an aryloxy phosphorodichloridate and a WO 2008/062206 PCT/GB200'/004480 9 suitably protected amino acid derivative. Alternatively, phosphate chemistry may be used with suitable condensing agents. Each of Ar, RI, RL R 3 and R 4 can be substituted with one, two, three, four, five or more 5 substituents independently selected from the group comprising electron donating and electron withdrawing moieties. Substituents on Ar are suitably independently selected from the group consisting of hydroxy (OH-), acyl (R'C(=O)-), acyloxy (R'C(=O)O-), nitro (-NO 2 ), amino (-NH 2 ), 10 SO 3 H, -SH, R'S-, wherein R' is independently selected from the same group set out above as RI; carboxyl (-COOH), CI-esters, CI 4 aldehyde, cyano (-CN), C 1 .alkylamino, C 1 . 6 dialkylamino, thiol, chloro, bromo, fluoro, iodo, C,.

6 alkyl, C2-6alkenyl, C 1

.

6 alkoxy-C,. 6alkyl, C,.alkoxy-Cs . 1 oaryl, Cs 57 cycloalkyl, Cs

.

ilcycloalkyl-Ci.

6 alkyl, C 5 .7cycloalkenyl, Cs 7 cycloalkynyl, Cs.iarylC 1

.

6 alkyl, CI-6alkylCs.1iaryl, Cs.

1 aryl, C 1 .luoroalkyl and C 2 . 15 6 fluoroalkenyl. Each substituent can be substituted by any other substituent. Substituents on RI, R 2 , R 3 and R 4 are independently selected from the group consisting of hydroxy (-OH), acyl (R'C(C=0)-), acyloxy (R'C(O=)O-), nitro (-NO 2 ), amino (-NH 2 ), amido (-CONH 2 ), -S0 3 -H, -SH, -SR', wherein R' is independently selected from the same 20 group set out above as R 1 , carboxyl (-COOH), C 1 .- esters, C-aldehyde, cyano (CN-), Ci. 6alkylamino, C 1 -6dialkylamino, thiol, chloro, bromo, fluoro, iodo, Cs.

7 cycloalkyl, C 5

.

7 cycloalkenyl, C 5

.

7 cycloalkynyl, Cs-izaryl, C 5 .iiarylC.6alkyl and C 5 -zoheterocyclyl. Each substituent can be substituted by any other substituent. 25 R, and R 2 are suitably independently selected from the group consisting of H, C1.ioalkyl,

C

2

-

10 alkenyl, C 2 -joalkoxyC,.oalkyl, C 1 .ioalkoxyC 6 .,oaryl, C 2

.

10 alkynyl, C 3

-

20 cycloalkyl, C 3 . 2 ocycloalkenyl, C4- 2 0 cycloalkynyl, and C 5

.,

0 heterocyclyl. R, and R 2 are suitably selected from the side chains of natural or synthetic amino acids. 30 RI and/or R 2 are preferably a side chain of a natural amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, serine, threonine, lysine, arginine, histidine, aspartic acid, glutamic acid, WO 2008/062206 PCT/GB2007/004480 10 asparagines, glutamine, cysteine and methionine. Specifically, Ri and/or R 2 are preferably selected from the group consisting of H, CH 3 , -CH(CH 3

)

2 , -CH 2

CH(CH

3 )2, CH(CH 3

)(CH

2

CH

3 ), -CH 2 Ph, -CH 2 Ph-OH, -CH 2 SH, -CH 2

CH

2

SCH

3 , -CH 2 OH, CH(CH 3 XOH), -CH 2

CH

2

CH

2

CH

2

NH

3 *, -CH 2

CH

2

CH

2 NHC(=NH2*)NH2, -CH 2 C(0)O-, 5 -CH 2

CH

2 C(0)0-, -CH 2 C(O)NHz, -CH 2

CH

2

C(O)NH

2 , CH2

H

2 C HN,.NH / NH 10 and wherein R, and R 4 together can form a 5-membered heterocyclic ring having the structure HN-C' 15 R 3 and R 4 are suitably independently selected from the group consisting of H Ci.ioalkyl,

C

2

.

1 oalkenyl, C 1

.

1 oalkoxy, Ci.ioalkoxyC 1

.

1 oalkyl, Ci.ioalkoxyC,-ioaryl,

C

2 -oalkynyl, C 3 20 cycloalkyl, C 3

-

2 0 cycloalkenyl, C4-20cycloalkynyl, and C 5

.

2 oheterocyclyl.

R

3 is suitably selected from the group consisting of H, Ci.isalkyl, C 3 -20cycloalkyl and 20 benzyl.

R

4 is suitably selected from the group consisting of H, C 1 .isalkyl, C 3 .20cycloalkyl and C5 2 heterocyclyl. R 4 is particularly suitably selected from the group consisting of H, methyl, ethyl, propyl, butyl, pentyl, hexyl and cyclohexyl. 25 In a preferred embodiment, R, and R 2 are methyl or are linked to form a closed 5 membered heterocyclic or carbocyclic ring, for example, as present in proline. As used herein,. the term "alkyl" refers to a straight or branched saturated monovalent 30 cyclic or acyclic hydrocarbon radical, having the number of carbon atoms as indicated (or where not indicated, an acyclic alkyl group preferably has 1-20, more preferably 1-6, more preferably 1-4 carbon atoms and a cyclic alkyl group preferably has 3-20, preferably 3-10, more preferably 3-7 carbon atoms), optionally substituted with one, two, three or more WO 2008/062206 PCT/GB2007/004480 11 substituents independently selected from the group set out above with respect to substituents that may be present on RI, 1%, R 3 and R 4 . By way of non-limiting examples, suitable alkyl groups include methyl, ethyl, propyl, butyl, pentyl, hexyl, octyl, nonyl and dodecyl. 5 As used herein, the term "alkenyl" refers to a straight or branched unsaturated monovalent acyclic or cyclic hydrocarbon radical having one or more C=C double bonds and having the number of carbon atoms as indicated (or where not indicated, an acyclic alkenyl group preferably has 2-20, more preferably 2-6, more preferably 2-4 carbon atoms and a cyclic 10 alkenyl group preferably has 4-20, more preferably 4-6 carbon atoms), optionally substituted with one, two, three or more substituents independently selected from the group set out above with respect to substituents that may be present on R 1 , R2, R 3 and R 4 . By way of non-limiting examples, suitable alkenyl groups include vinyl, propenyl, butenyl, pentenyl and hexenyl. 15 As used herein, the term "alkynyl" refers to a straight or branched unsaturated monovalent acyclic or cyclic hydrocarbon radical having one or more triple C=C bonds and having the number of carbon atoms as indicated (or where not indicated, an acyclic alkynyl group preferably has 2-20, more preferably 2-6, more preferably 2-4 carbon atoms and a cyclic 20 alkynyl group preferably has 7-20, more preferably 8-20 carbon atoms), optionally substituted with one, two, three or more substituents independently selected from the group set out above with respect to substituents that may be present on RI, R 2 , R 3 and R 4 . As use herein, the term "alkoxy" or the term "alkyloxy" refers to the group alkyl-O-, where 25 alkyl is as defined above and where the alkyl moiety may optionally be substituted by one, two, three or more substituents as set out above for alkyl. By way of non-limiting examples, suitable alkoxy groups include methoxy, ethoxy, n-propoxy, iso-propoxy, n butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy and 1,2-dimethylbutoxy. The term "cycloalkyloxy" refers to the group cyclicalkyl-O-, where cyclicalkyl is as defined above 30 and where the cyclicalkyl moiety may be optionally substituted by one, two, three or more substituents as set out above for alkyl.

WO 2008/062206 PCT/GB2007/004480 12 As used herein, the term "aryloxy" refers to the group aryl-0-, where aryl is as defined below and where the aryl moiety may optionally be substituted by one, two, three or more substituents as set out above with respect to the group Ar. 5 As used herein, the term "alkoxyalkyl" refers to an alkyl group having an alkoxy substituent. Binding is through the alkyl group. The alkyl moiety and the alkoxy moiety are as defined herein with respect to the definitions of alkyl and alkoxy, respectively. The alkoxy and alkyl moieties may each be substituted by one, two, three or more substituents as set out above with regard to the definition of alkyl. 10 As used herein, the term "alkoxyaryl" refers to an aryl group having an alkoxy substituent. Binding is through the aryl group. The alkoxy moiety and the aryl moiety are as defined herein with respect to the definitions of alkoxy and aryl, respectively. The alkoxy and aryl moieties may each be substituted by one, two, three or more substituents, as defined herein 15 with regard to the definitions of alkoxy and aryl, respectively. As used herein, the term "cycloalkylaryl" refers to an aryl group having a cyclic alkyl substitutent. Binding is through the aryl group. The cycloalkyl moiety and the aryl moiety are as defined herein with respect to the definitions of cycloalkyl and aryl, respectively. 20 The cycloalkyl moiety and the aryl moiety may each be optionally substituted by one, two, three or more substituents as set out herein with regard to the definitions of alkyl and aryl, respectively. Except where otherwise stated with respect to the definition of "Ar", as used herein the 25 term "aryl" refers to a monovalent unsaturated aromatic carbocyclic radical having one, two, three, four, five or six rings, preferably one, two or three rings, which may be fused or bicyclic. An aryl group may optionally be substituted by one, two, three or more substituents as set out above with respect to optional substituents that may be present on the group Ar. Preferred aryl groups are:. an aromatic monocyclic ring containing 6 carbon 30 atoms; an aromatic bicyclic or fused ring system containing 7, 8, 9 or 10 carbon atoms; or an aromatic tricyclic ring system containing 10, 11, 12, 13 or 14 carbon atoms. Non limiting examples of aryl include phenyl and naphthyl. Preferred substituent groups are independently selected from hydroxy (-OH), acyl (R'-C(=O)-), acyloxy (R'-C(=0)-O-), WO 2008/062206 PCT/GB2007/004480 13 nitro (-NO 2 ), amino (-NH 2 ), -S0 3 H, -SH, -SR', wherein R' is independently selected from the same groups as R 1 ; carboxyl (-COOH), cyano (-CN), C 1 .alkylamino, C 1 . 6dialkylamino, thiol, chloro, bromo, fluoro and iodo. 5 As used herein, the term "heterocyclyl" refers to a saturated or partially unsaturated heterocyclic ring system having one, two, three, four, five or six rings, preferably one, two or three rings, which may be fused or bicyclic, and having contained within the ring or rings at least one member selected from the group consisting of N, 0 and S. The prefix "C5.20" or "C5.10" used before heterocyclyl means, respectively, a five to twenty or a five to 10 ten membered ring system at least one of which members is selected from the group consisting of N, 0 and S. Preferred heterocyclyl systems are: a monocyclic ring system having five members of which at least one member is a N, 0 or S atom and which optionally contains one additional 0 atom or one, two or three additional N atoms; a monocyclic ring having six members of which one, two or three members are a N atom; a 15 bicyclic ring system having nine members of which at least one member is a N, 0 or S atom and which optionally contains one, two or three additional N atoms; or a bicyclic ring system having ten members of which one, two or three members are a N atom. Examples include, and are not limited to, pyrrolinyl, pyrrolidinyl, 1,3-dioxolanyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl or piperazinyl. 20 Available carbon atoms and/or heteroatoms of the "heterocyclyl" ring systems described above may be substituted on the ring with one or more heteroatoms. Where the ring(s) is substituted with one or more heteroatoms, heteroatom substituents are selected from oxygen, nitrogen, sulphur and halogen (F, Cl, Br and 1). Where the ring(s) is substituted 25 with one or more heteroatoms, preferably there are 1, 2, 3 or 4 heteroatom substituents selected from the group consisting of oxygen, nitrogen and/or halogen. Preferred substituent groups are independently selected from hydroxy, acyl, acyloxy, nitro, amino,

SO

3 H, SH, SR', wherein R' is independently selected from the same groups as R; carboxyl, cyano, CI- 6 alkylamino, C,.6dialkylamino, thiol, chloro, bromo, fluoro and iodo. 30 The process is preferably carried out in the presence of a suitable solvent.

WO 2008/062206 PCT/GB2007/004480 14 Suitable solvents include hydrocarbon solvents such as benzene and toluene; ether type solvents such as diethyl ether, tetrahydrofuran, diphenyl ether, anisole and dimethoxybenzene; halogenated hydrocarbon solvents such as methylene chloride, chloroform and chlorobenzene; ketone type solvents such as acetone, methyl ethyl ketone 5 and methyl isobutyl ketone; alcohol type solvents such as methanol, ethanol, propanol, isopropanol, n-butyl alcohol and tert-butyl alcohol; nitrile type solvents such as acetonitrile, propionitrile and benzonitrile; ester type solvents such as ethyl acetate and butyl acetate; carbonate type solvents such as ethylene carbonate and propylene carbonate; and the like. These may be used singly or two or more of them may be used in admixture. 10 Preferably an inert solvent is used in the process of the present invention. The term "inert solvent" means a solvent inert under the conditions of the reaction being described in conjunction therewith including, for example, benzene, toluene, acetonitrile, tetrahydrofuran, dimethylformamide, chloroform, methylene chloride (or 15 dichloromethane), diethyl ether, ethyl acetate, acetone, methylethyl ketone, methanol, ethanol, propanol, isopropanol, tert-butanol, dioxane, pyridine, and the like. Tetrahydrofuran is particularly preferred. Preferably the process of the present invention is carried out under substantially dry 20 conditions. As used herein, the term "stereoisomer" defines all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of the present invention 25 may possess. Where the compounds according to this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. Where the processes for the 30 preparation of the compounds according to the invention give rise to mixture of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography, The compounds may be prepared in stereochemically mixed form or individual enantiomers may be prepared by standard techniques known to those WO 2008/062206 PCT/GB2007/004480 15 skilled in the art, for example, by enantiospecific synthesis or resolution, formation of diastereomeric pairs by salt formation with an optically active acid, followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and 5 removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. Furthermore, it should be appreciated that the phosphate centre is chiral in the compounds 10 of the present invention and the compounds may exist as Rp and Sp diastereoisomers. The composition of the compound may be mixed Rp and Sp or one pure diastereomer. Preferably the compound is a substantially pure single isomer. There may be a mixture of 1:1 Rp to Sp diastereomers. Alternatively, there may be a ratios 15 of 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:15, 1:20, 1:50 or 1:100 of Rp to Sp diastereomers or vice versa. The term "solvate" means a compound of as defined herein, or a pharmaceutically acceptable salt of a compound of structure (I) or (II), wherein molecules of a suitable 20 solvent are incorporated in the crystal lattice. A suitable solvent is physiologically tolerable at the dosage administered. Examples of suitable solvents are ethanol, water and the like. When water is the solvent, the molecule is referred to as a hydrate. The compounds of the present invention may also be present in the form of pharmaceutical 25 acceptable salts. For use in medicine, the salts of the compounds of this invention refer to non-toxic "pharmaceutically acceptable salts." FDA approved pharmaceutical acceptable salt forms (Ref. International J. Pharm. 1986, 33, 201-217; J. Pharm. Sci., 1977, Jan, 66 (1)) include pharmaceutically acceptable acidic/anionic or basic/cationic salts. 30 Pharmaceutically acceptable acidic/anionic salts include, and are not limited to acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, glyceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, WO 2008/062206 PCT/GB2007/004480 16 hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, pamoate, pantothenate, phosphate, diphospate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, teoclate, tosylate and triethiodide. 5 Pharmaceutically acceptable basic/cationic salts include, and are not limited to aluminum, benzathine, calcium, chloroprocaine, choline, diethanolamine, ethylenediamine, lithium, magnesium, potassium, procaine, sodium and zinc. 10 The present invention includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds which are readily convertible in vivo into the required compound. Thus, in the methods of treatment of the present invention, the term "administering" shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a 15 compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the subject. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985. 20 Pharmaceutically acceptable ester derivatives in which one or more free hydroxy groups are esterified in the form of a pharmaceutically acceptable ester are particularly prodrug esters that may be convertible by solvolysis under physiological conditions to the compounds of the present invention having free hydroxy groups. 25 Pharmaceutical compositions for use in accordance with the present invention may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. These pharmaceutical compositions may be manufactured in a manner that is itself known, e.g., by means of conventional 30 mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. Proper formulation is dependent upon the route of administration chosen.

WO 2008/062206 PCT/GB2007/004480 17 The compound having formula I or pharmaceutical composition according to the present invention can be administered to a patient, which may be homo sapiens or animal, by any suitable means. 5 The medicaments employed in the present invention can be administered by oral or parenteral routes, including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration. 10 For oral administration, the compounds of the invention will generally be provided in the form of tablets or capsules, as a powder or granules, or as an aqueous solution or suspension. Tablets for oral use may include the active ingredient mixed with pharmaceutically 15 acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while cornstarch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating 20 agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract. Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed 25 with a solid diluent, and soft gelatin capsules wherein the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil. Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate. 30 Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

WO 2008/062206 PCT/GB2007/004480 18 For intramuscular, intraperitoneal, subcutaneous and intravenous use, the compounds of the invention will generally be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity. Suitable aqueous vehicles include Ringer's 5 solution and isotonic sodium chloride. Aqueous suspensions according to the invention may include suspending agents such as cellulose derivatives, sodium alginate, polyvinyl pyrrolidone and gum tragacanth, and a wetting agent such as lecithin. Suitable preservatives for aqueous suspensions include ethyl and n-propyl p-hydroxybenzoate. 10 The compounds of the invention may also be presented as liposome formulations. In general a suitable dose will be in the range of 0.1 to 300 mg per kilogram body weight of the recipient per day. A preferred lower dose is 0.5 mg per kilogrm body weight of reepient per day, a more preferred lower dose is I mg per kilogram body weight of 15 recipient per day. A suitable dose is preferably in the range of 1 to 50 mg per kilogram body weight per day, and more preferably in the range of 1 to 10 mg per kilogram body weight per day. The desired dose is preferably presented as two, three, four, five or six or more sub-doses administered at appropriate intervals throughout the day. These sub-doses may be administered in unit dosage forms, for example, containing 10 to 1500 mg, 20 preferably 20 to 1000 mg, and most preferably 50 to 700 mg of active ingredient per unit dosage form. Examples Embodiments of the present invention will now be described by way of example only with 25 respect to the following examples. Target compounds were prepared by reacting the appropriate nucleoside, or its modified precursor, with the required phosphorochloridate. The latter reagents were prepared by published methods from aryl phosporodichloridates with amino acid ester hydrochlorides. Several examples are given. 30 Standard procedure C2: Preparation of 2', 3'-cyclopentyldyn-modf'ied-nucleoside phosphoramidates WO 2008/062206 PCT/GB2007/004480 19 tBuMgCl (2.0 mol. equivalent) and 2',3'-cyclopentylidene, 4'-azido-cytidine (1.0 mol. equivalent) were dissolved in dry tetrahydrofuran (THF) (31 mol. equivalent) and stirred for 15 minutes. Then a IM solution of the appropriate phosphorochloridate (2.0 mol. equivalent) in dry THF was added dropwise, then stirred overnight. A saturated solution of 5 NH 4 CI was added and the solvent was removed under reduced pressure to give a yellow solid, which was consequently purified. Standard procedure C3: Preparation ofphosphoramidates of modeled nucleoside 2', 3'-cyclopentylidene, modified nucleoside phosphoramidates were dissolved in a 10 solution 80% of formic acid in water for 4 hours. The solvent was removed under reduced pressure to give a white solid which was consequently purified. Standard procedure C4: Preparation ofphosphoramidates of modified nucleoside 2', 3'-isopropilidene, modified nucleoside phosphoramidates were dissolved in a solution 15 60% of acetic acid in water at 900 C overnight. The solvent was removed under reduced pressure to give a white solid which was consequently purified. Example 1 Synthesis of #-2'-methyl-adenosine (CHC1) NH2 N HO 20 OH OH N6-tert-butanoyl-#-2'-methyl-2',3',5'-tribenzoyl-adenosine (400 mg, 0.590 mmol) was .added to a solution of MeOH saturated with ammonia, and stirred at room temperature. After 12 hours the solvent was removed and the obtained solid was purified by column 25 chromatography in gradient starting with a mixture of CHCl 3 /MeOH 9:1 then 8:2. The pure product was obtained as a white solid (120 mg, 0.427 mmol, 72%). 8 H (d 6 -DMSO): 8.47 (1H, s, H8-adenosine), 8.15 (1H, s, H2-adenosine), 7.30 (1H, s,

NH

2 6-adenosine), 5.95 (IH, s, HI'-adenosine), 5.25-5.21 (3H, m, OH5'-adenosine, OH3' adenosine, OH2'-adenosine), 4.12-4.05 (1H, d, H3'-adenosine, J= 8.6 Hz), 3.91 (1H, m, WO 2008/062206 PCT/GB2007/004480 20 H4'-adenosine), 3.84 (1H, m, H5'-adenosine), 3.70 (IH, m, H5'-adenosine), 0.77 (3H, s,

CH

3 2'-adenosine); Sc (da-DMSO): 156.02 (1C, C6-adenosine), 152.53 (1 C, C2-adenosine), 149.01 (1C, C4-adenosine), 138.68 (1C, C8-adenosine), 118.67 (IC, C5-adenosine), 90.78 (IC, C1'-adenosine), 82.52 (1C, C4'-adenosine), 78.46 (IC, C2'-adenosine), 71.63 (IC, 5 C3'-adenosine), 59.47 (IC, C5'-adenosine), 19.83 (1C, CH 3 -2'-adenosine). Anal. Calc. for Cn 1

H

1 sN 5

O

4 : C 46.97%, H 5.38%, N 24.90%. Found: C 46.67%, H 5.22%, N 24.20%. Example 2 Synthesis of 2', 3'-0,0-cyclopentylidyn-p-2'-methyl-adenosine 5'-O-[phenyl(ethoxy 10 L-alaninyl)] phosphate Oi NH2 % O N / \ ONH N< N 0 Prepared according to Standard Procedure C2, from 2', 3'-O,0-cyclopentylidyn-p-2' methyl-adenosine (60 mg, 0.172 nmol), 'BuMgCI (0.5 ml, IM solution in THF, 0.519 15 mmol) and a-naphthyl(ethoxy-L-alaninyl) phosphorochloridate (0.5 ml of solution IM in THF, 0.519 mmol). The crude was purified by column chromatography, using as eluent CHC1 3 /MeOH (95:5). The obtained pure product was a white solid (30 mg, 0.046 mmol, 26%). 8p (d-CH 3 0H): 4.31, 4.26; 8n (d 4

-CH

3 0H): 8.19 (1H, s, H2-adenosine), 8.10 (1H, s, H8 20 adenosine), 7.88 (1H, m, CH-naphthyl), 7.73 (1H, m, CH-naphthyl), 7.57-7.52 (4H, m, CH-naphthyl), 7.45-7.43 (1H, m, CH-naphthyl), 6.26 (1H, m, H1'-adenosine), 4.56-4.42 (4H, m, H4'-adenosine, H3'-adenosine, 2 H5'-adenosine), 4.08 (3H, m, CHt, CH 2 -ethyl), 2.21-2.09 (2H, m, CH 2 -cyclopentyl), 1.76-1.71 (6H, m, 3 CH 2 -cyclopentyl), 1.35 (3H, d,

CH

3 -alanine, J= 6.9 Hz), 1.25 (3H, m, CH 3 -ethyl), 0.95 (3H, s, CH 3 2'-adenosine). 25 Synthesis of fp-2'-methyl-adenosine 5'-0-[a-naphthyl(ethoxy-L-alaninyl)] phosphate (CHC2) WO 2008/062206 PCT/GB2007/004480 21 O' NH2 / O ONH N N OH OH Prepared according to Standard Procedure C3, from 2', 3'-0,0-cyclopentylidyn-p-2' methyl-adenosine 5'-O-[a-naphthyl(ethoxy-L-alaninyl)] phosphate (30 mg, 0.036 mmol), 5 and 10 ml of a solution 80% of HCOOH in water. The crude was purified by column chromatography, using as eluent for the first CHCl 3 /MeOH (95:5) followed by a semi preparative HPLC. The obtained pure product was a white solid (4 mg, 0.007 mmol, 19%). 8p (d 4

-CH

3 0H): 4.23, 4.20; 6n (drCH 3 0H): 8.24-8.19 (3H, m, H2-adenosine, H8 adenosine, CH-naphthyl), 7.90 (lH, m, CH-naphthyl), 7.63 (1H, CH-naphthyl), 7.53 (4H, 10 m, CH-naphthyl), 7.41 (1H, m, CH-naphthyl), 6.12 (1H, d, H1'-adenosine, J= 2.1 Hz), 4.61-4.59 (2H, d, H3'-adenosine, H4'-adenosine), 4.30 (IH, m, H5'-adenosine), 4.02-3.99 (3H, m, CHa, CH 2 -ethyl), 1.37 (3H, n, CH 3 -alanine), 1.27 (3H, m, CH 3 -ethyl), 0.95 (3H, s, CH 3 -2'-adenosine). MS (ES) m/e: 609.2 (MNa*, 100%); Accurate mass: C 2 6H 31

N

6 0sNaP required 609.1846, 15 found 609.1839. Example 3 Synthesis of 2', 3'-0,0-cyclopentylidyn-i-2'-methyl-adenosine 5'-O-[phenyl(benzoxy I-alaninyl)] phosphate WO 2008/062206 PCT/GB2007/004480 22 O N NH2 O N O O Prepared according to Standard Procedure C2, from 2', 3'-O,O-cyclopentylidyn-#l-2' methyl-adenosine (40 mg, 0.115 mmol), 'BuMgCl (0.35 ml, IM solution in THF, 0.345 5 mmol) and c-naphthyl(benzoxy-L-alaninyl) phosphorochloridate (0.35 ml of solution IM in THF, 0.345 mmol). The crude was purified by column chromatography, using as eluent CHC13/MeOH (95:5). The obtained pure product was a white solid (20 mg, 0.028 mmol, 24%). Sp (d 4

-CH

3 0H): 4.34, 4.18; 8H (drCH 3 0H): 8.50 (1H, s, H2-adenosine), 8.17 (1H, s, H8 10 adenosine), 7.90 (1H, m, CH-naphthyl), 7.71 (1H, mn, CH-naphthyl), 7.69 (1H, CH benzyl), 7.55-7.50 (3H, m, CH-naphthyl, 2 CH-benzyl), 7.42-7.27 (6H, m, 4 CH-naphthyl, 2 CH-benzyl), 6.25 (IH, d, H1'-adenosine), 5.10 (2H, s, CH 2 -benzyl), 4.61 (1H, m, H3' adenosine), 4.41 (1H, m, H4'-adenosine), 4.15 (1H, m, CHcx), 3.95 (1H, m, H5'-adenosine, J= 12.2 Hz), 3.85 (1H, m, H5'-adenosine, J= 12.2 Hz), 2.12-2.03 (2H, m, CH 2 15 cyclopentyl), 1.79-1.72 (6H, m, 3 CHrcyclopentyl), 1.37 (3H, d, CH 3 -alanine, J- 7.2 Hz), 0.89 (3H, s, CHr2'-adenosine). Synthesis of P-2'-methyl-adenosine 5'-0-[a-naphthyl(benzoxy.L-alaninyl)j phosphate (CHC3) WO 2008/062206 PCT/GB2007/004480 23 O9 NH2 O N N PO, , NH N N OH OH Prepared according to Standard Procedure C3, from 2', 3'-O,O-cyclopentylidyn-p-2' methyl-adenosine 5'-0-[ot-naphthyl(benzoxy-L-alaninyl)) phosphate (30 mg, 0.036 5 mmol), and 10 ml of a solution 80% of HCOOH in water. The crude was purified by column chromatography, using as eluent for the first CHC]3/MeOH (95:5) followed by a semi--preparative HPLC. The obtained pure product was a white solid (5 mg, 0.008 nnol, 21%). Sp (ds-CH 3 0H): 4.25, 4.14; SH (d 4

-CH

3 0H): 8.04-7.95 (3H, m, H2-adenosine, H8 10 adenosine, CH-naphthyl), 7.68 (IH, m, CH-naphthyl), 7.48 (IH, m, CH-naphthyl), 7.32 7.23 (3H, in, CH-naphthyl, 2 CH-benzyl), 7.16 (1H, m, CH-naphthyl), 7.05 (6H, m, 3 CH naphthyl, 3 CH-benzyl), 5.88 (IH, d, Hl'-adenosine, J= 2.9 Hz), 4.85-4.65 (2H, m, CH 2 benzyl), 4.37-4.35 (2H, d, H3'-adenosine, H4'-adenosine), 4.06 (2H, m, HS'-adenosine), 3.88-3.83 (1H, m, CHa), 1.35 (3H, in, CH 3 -alanine), 0.88 (3H, s, CHr2'-adenosine). 15 MS (ES) m/e: 671.2 (MNa*, 100%); Accurate mass: C 31

H

33

N

6 ONaP required 671.1990, found 671.1995. Example 4 Synthesis of 2', 3'-0,0-cyclopentylidyn-pi-2'-methyl-adenosine 5'-0-[phenyl(tert 20 butoxy-L-alaninylfl phosphate WO 2008/062206 PCT/GB2007/004480 24 0 K NH2 O N N / \ O NH N N O N 0 Prepared according to Standard Procedure C2, from 2', 3'-O,O-cyclopentylidyn-#-2' methyl-adenosine (60 mg, 0.172 mmol), t BuMgC1 (0.51 ml, 1M solution in THF, 0.51 5 mmol) and a-naphthyl(tert-butoxy-L-alaninyl) phosphorochloridate (0.5 ml of solution 1M in THF, 0.519 mmol). The crude was purified by column chromatography, using as eluent CHCl 3 /MeOH (95:5). The obtained pure product was a white solid (27 mg, 0.039 mmol, 22%). 8p (d 4

-CH

3 0H): 4.37, 4.28; 8H (d 4

-CH

3 0H): 8.21 (1H, s, H2-adenosine), 8.13 (1H, s, H8 10 adenosine), 7.85 (1H, m, CH-naphthyl), 7.73 (1H, m, CH-naphthyl), 7.57-7.52 (41, m, CH-naphthy]), 7.43-7.41 (IH, m, CH-naphthyl), 6.25 (1H, m, H1'-adenosine), 4.55-4.40 (41H, m, H4'-adenosine, H3'-adenosine, 2 H5'-adenosine), 4.05 (1H, m, CHcc), 2.20-2.12 (2H, m, CH2-cyclopentyl), 1.79-1.69 (6H, m, 3 CH 2 -cyclopentyl), 1.36 (9H, 3 CH 3 -tert butyl), 1.25 (3H, d, CH 3 -alanine, J- 6.9 Hz), 0.96 (3H, s, CH 3 -2'-adenosine). 15 Synthesis of p.2'-methyl-adenosine 5'-0-I-naphthyl(tert-butoxy-L-aaniny)] phosphate (CHC4) O- NH 2 > o K/N N O NH OH OH WO 2008/062206 PCT/GB2007/004480 25 Prepared according to Standard Procedure C3, from 2', 3'-O,O-cyclopentylidyn-#-2' methyl-adenosine 5'-0-[a-naphthy1(tert-butoxy-L-alaninyl)] phosphate (27 mg, 0.039 mmol), and 10 ml of a solution 80% of HCOOH in water. The crude was purified by column chromatography, using as eluent for the first CHCl 3 /MeOH (95:5) followed by a 5 semi-preparative HPLC. The obtained pure product was a white solid (10 mg, 0.016 mmol, 41%). 8p (drCH 3 0H): 4.20, 4.08; 8H (d 4

-CH

3 0H): 8.20-8.15 (3H, m, H2-adenosine, H8 adenosine, CH-naphthyl), 7.81 (1H, m, CH-naphthyl), 7.60 (1H, CH-naphthyl), 7.54 (4H, m, CH-naphthyl), 7.39 (1H, m, CH-naphthyl), 6.15 (1H, d, H1'-adenosine), 4.63-4.57 (2H, 10 d, H3'-adenosine, H4'-adenosine), 4.31 (1H, m, H5'-adenosine), 4.00-3.97 (1H, m, CHc), 1.39 (9H, 3 CH 3 -tert-butyl), 1.27 (3H, m, CH 3 -alanine), 0.97 (3H, s, CH 3 -2'-adenosine). Example 5 Synthesis of p-2'-methyl-guanosine (CHC5) 0 N N NH2 HO Os 15 OH OH N2-acetyl-p-2'-methyl-2',3',5'-tribenzoyl-guanosine (1.42 g, 2.18 mmol) was added to a solution of MeOH saturated with ammonia, and stirred at room temperature. After 12 hours the solvent was removed and the obtained solid was purified by column 20 chromatography using as eluent a mixture of CHCl 3 /MeOH 8:2. The pure product was obtained as a white solid (565 mg, 1.90 mmol, 87%). 8n (d 6 -DMSO): 10.52 (1H, s, NH1-guanosine), 8.48 (1H, s, H8-guanosine), 6.52 (2H, s,

NH

2 2-guanosine), 5.73 (1H, s, H1'-guanosine), 5.24 (1H, d, OH3'-guanosine, .J 6.3 Hz), 5.11 (1H, ma, OH5'-guanosine), 5.03 (1H, s, OH2'-guanosine), 3.97 (1H, m, H3' 25 guanosine), 3.85-3.79 (2H, m, H4', H5'-guanosine), 3.66 (111, d, H5'-guanosine, J= 12.2 Hz), 0.81 (3H, s, CH 3 -2'-guanosine); Sc (d 6 -DMSO): 156.72 (IC, C6-guanosine), 153.68 (IC, C2-guanosine), 150.77 (IC, C4-guanosine), 135.07 (IC, C8-guanosine), 116.38 (IC, WO 2008/062206 PCT/GB2007/004480 26 C5-guanosine), 90.10 (IC, C1'-guanosine), 82.30 (IC, C3'-guanosine), 78.52 (1C, C2' guanosine), 71.63 (IC, C4'-guanosine), 59.40 (IC, C5'-guanosine), 19.96 (IC, CH3-2' guanosine). MS (ES) m/e: 320.2 (MNa*, 100%); Accurate mass: C 11

H

15 NsOsNa required 320.0968, 5 found 320.0971. Example 6 Synthesis of 2', 3'-0,0-isopropylidyn-p-2'-methyl-guanosine 5'-0-[phenyl(benzoxy L-alaninyl)] phosphate 09 0 NH o NHo /NN N NH 2 10 Prepared according to Standard Procedure C2, from 2', 3'-O,O-isopropylidyn-#-2'-methyl guanosine (170 mg, 0.503 mmol), tBuMgCl (1.0 ml, IM solution in THF, 1.006 mmol) and a-naphthyl(benzoxy-L-alaninyl) phosphorochloridate (1.0 ml of solution iM in THF, 15 1.006 mmol). The crude was purified by column chromatography, using as eluent CHC1 3 /MeOH (95:5). The obtained pure product was a white solid (70 mg, 0.098 mmol, 19%). 8p (d 4

-CH

3 0H): 4.53, 4.40; S1 (drCH 3 0H): 8.28 (111, s, H8-guanosine), 7.84 (1H, m, CH naphthyl), 7.77-7.71 (IH, m, CH-benzyl), 7.55-7.49 (4H, m, 2 CH-naphthyl, 2 CH-benzyl), 20 7.44-7.29 (6H, m, 4 CH-naphthyl, 2 CH-benzyl), 6.06 (IH, d, H1'-guanosine), 5.10 (2H, s,

CH

2 -benzyl), 4.59 (1H, m, H3'-guanosine), 4.52-4.45 (1H, m, H4'-guanosine), 4.34 (2H, H5'guanosine), 4.14 (1H, m, CHa), 1.59 (3H, d, CH 3 -isopropylidine, J= 10.4 Hz), 1.37 (6H, d, CH 3 -alanine, CH 3 -isopropylidine), 0.99 (3H, d, CH 3 -2'-guanosine, .1= 20.11 Hz). 25 Synthesis of #-2'-methyl-guanosine 5'-0-[c.-naphthyl(benzoxy-L-alaninyl)] phosphate (CHC6) WO 2008/062206 PCT/GB2007/004480 27 09 0 0 NH < / P,,NH N: N NH 2 -' OH OH Prepared according to Standard Procedure C4, from 2', 3'-0,0-isopropylidyn-#-2'-methyl guanosine 5'-O-[a-naphthyl(benzoxy-L-alaninyl)I phosphate (70 mg, 0.098 mmol), and 10 5 ml of a solution 60% of CH 3 COOH in water at 90* C for 15 hours. The crude was purified by column chromatography, using as eluent for the first CHC1 3 /MeOH (85:5) followed by a semi-preparative HPLC. The obtained pure product was a white solid (12 mg, 0.018 mmol, 18%). 8p (d 4

-CH

3 0H): 4.25, 4.14; 8H (drCH 3 0H): 8.17 (1H, m, HS-guanosine), 7.88 (1H, m, 10 CH-naphthyl), 7.79 (IH, m, CH-naphthyl), 7.53 (2H, in, CH-naphthyl, CH-benzyl), 7.42 7.40 (1H, m, CH-naphthyl), 7.36-7.21 (7H, in, 3 CH-naphthyl, 4 CH-benzyl), 6.05 (IH, d, H1'-guanosine, J= 8.4 Hz), 5.15-4.90 (2H, m, CH 2 -benzyl), 4.58-4.49 (2H, d, H3' guanosine, H4'-guanosine), 4.44-4.34 (2H, , H5'-guanosine), 4.17-4.11 (IH, m, CHa), 1.37 (3H, m, CH 3 -alanine), 1.00 (311, s, CH 3 -2'-guanosine). 15 MS (ES) m/e: 687.2 (MNa, 100%); Accurate mass: C 31

H

33

N

6

O

9 NaP required 687.1954, found 687.1944. Example 7 Synthesis of 2', 3'-0,0-lsopropylidyn-Af-2'-methyl-guanosine 5'-O-[phenyl(ethoxy-L 20 alaninyl)] phosphate O O %\4O NNH / 0 ,N 0 O O WO 2008/062206 PCT/GB2007/004480 28 Prepared according to Standard Procedure C2, from 2', 3'-O,O-isopropylidyn-p-2'-methyl guanosine (220 mg, 0.652 mmol), 'BuMgCl (1.3 ml, IM solution in THF, 1.30 mmol) and a-naphthyl(ethoxy-L-alaninyl) phosphorochloridate (1.3 ml of solution IM in THF, 1.30 mmol). The crude was purified by column chromatography, using as fluent CHCl 3 /MeOH 5 (95:5). The obtained pure product was a white solid (35 mg, 0.054 mmol, 9%). 8p (dCH 3 0H): 4.41, 4.32; & (d 4

-CH

3 0H): 8.18 (1H, s, H8-guanosine), 7.88 (1H, m, CH naphthyl), 7.73 (1H, ma, CH-naphthyl), 7.59-7.52 (4H, m, 4 CH-naphthyl), 7.46-7.42 (IH, m, CH-naphthyl), 6.08 (1H, d, H1'-guanosine), 4.62-4.40 (4H, m, H3'-guanosine, H4' guanosine, H5'guanosine), 4.11-4.09 (3H, m, CHct, CH 2 -ethyl), 1.59 (3H, d, CH 3 10 isopropylidine, J- 13.2 Hz), 1.37 (6H, m, CH 3 -alanine, CH 3 -isopropylidine), 1.20 (3H, m,

CH

3 -ethyl), 1.00 (3H, m, CH 3 -2'-guanosine). Synthesis of f2'-methyl-guanosine 5'-0-[a-naphthyl(ethoxy-L-alaninyl)] phosphate (CHC7) oJ 0 o NH O PNH N N NH2 15 OH OH Prepared according to Standard Procedure C4, from 2', 3'-O,O-isopropylidyn-p-2'-methyl guanosine 5'-O-[a-naphthyl(ethoxy-L-alaninyl)] phosphate (35 mg, 0.054 mmol), and 10 ml of a solution 60% of CH 3 COOH in water at 90* C for 15 hours. The crude was purified 20 by column chromatography, using as eluent for the first CHCl 3 /MeOH (85:5) followed by a semi-preparative HPLC. The obtained pure product was a white solid (10 mg, 0.018 mmol, 3 1%). 8 P (d-CH 3 0H): 4.25, 4.14; 8 H (d 4

-CH

3 0H): 8.18 (1H, mn, H8-guanosine), 7.87 (IH, mn, CH-naphthyl), 7.71 (1H, m, CH-naphthyl), 7.53 (4H, m, 4 CH-naphthyl), 7.51-7.40 (1H, 25 m, CH-naphthyl), 5.93 (1H, d, H1'-guanosine), 4.62-4.57 (2H, m, H3'-guanosine, H4' guanosine), 4.24 (2H, m, H5'guanosine), 4.03-3.98 (3H, m, CHa, CH 2 -ethyl), 1.31 (3H, d,

CH

3 -alanine, .= 7.9 Hz), 1.15 (3H, m, CH 3 -ethyl), 1.00 (3H, m, CH 3 -2'-guanosine).

WO 2008/062206 PCTIGB2007/004480 29 MS (ES) m/e: 625.3 (MNa*, 100%); Accurate mass: C 26

H

3 lN 6

O

9 NaP required 625.1795, found 6251788. Anal. Calc. for C 26

H

3

IN

6 0 9 P: C 51.83%, H 5.19%, N 13.95%. Found: C 51.86%, H 5.10%, N 12.04%. 5 Example 8 Synthesis of 2', 3'-O,0-isopropylidyn-#-2'-methyl-gunosine 5'-O-[pbenyl(tert butoxy-L-alaninyl)] phosphate 0 NNH PN N NH2 0 0 10 Prepared according to Standard Procedure C2, from 2', 3'-0,0-isopropylidyn--2'-methyl guanosine (120 mg, 0.355 mol), 'BuMgCl (0.70 ml, IM solution in THF, 0.711 mmol) and ct-naphthyl(tert-butoxy-L-alaninyl) phosphorochloridate (0.70 ml of solution IM in THF, 0.711mmol). The crude was purified by column chromatography, using as eluent 15 CHCI 3 /MeOH (95:5). The obtained pure product was a white solid (24 mg, 0.036 mmol, 10%). 8p (drCH 3 0H): 4.41, 4.32; 8 H (d4CH 3 0H): 8.20 (1H, s, H8-guanosine), 7.89 (1H, m, CH naphthyl), 7.73 (11, mn, CH-naphthyl), 7.59-7.54 (4H, m, 4 CH-naphthyl), 7.49-7.42 (1H, m, CH-naphthyl), 6.07 (1H, d, H1'-guanosine), 4.62-4.40 (4H,.m, H3'-guanosine, H4' 20 guanosine, 2 H5'guanosine), 3.99-3.86 (1H, m, CHa), 1.58 (3H, d, CH 3 -isoprpylidine, J= 13.7 Hz), 1.44 (9H, s, 3 CH 3 -tert-butyl), 1.38-1.34 (611, m, CH 3 -alanine, CH 3 isoprpylidine), 1.01 (3H, m, CH 3 2'-guanosine). Synthesis of P-2'-methyl-guanosine 5'-O-[a-naphthyl(tert-butoxy-L-alaninyl)] 25 phosphate (CHC8) WO 2008/062206 PCT/GB2007/004480 30 NH 0 NH P 1N

NH

2 OH OH Prepared according to Standard Procedure C4, from 2', 3'-O,O-isopropylidyn-p-2'-methyl guanosine 5'-O-[a-naphthyl(tert-butoxy-L-alaninyl)] phosphate (24 mg, 0.036 mmol), and 5 10 ml of a solution 60% of CH 3 COOH in water. The crude was purified by column chromatography, using as eluent for the first CHCI 3 /MeOH (85:5) followed by a semi preparative HPLC. The obtained pure product was a white solid (4 mg, 0.018 mmol, 17%). 8p (d4CH 3 0H): 4.23, 4.10; 8H (d 4

-CH

3 0H); 8.20 (1H, m, H8-guanosine), 7.85 (1H, m, CH-naphthyl), 7.67 (1H, m, CH-naphthyl), 7.57 (4H, m, 4 CH-naphthyl), 7.53-7.43 (1H, 10 m, CH-naphthyl), 6.00 (1H, d, H1'-guanosine), 4.61-4.55 (2H, m, H3'-guanosine, H4' guanosine), 4.25 (2H, m, 2 H5'guanosine), 4.00-3.97 (1H, m, CHa), 1.47 (9H, s, 3 CH 3 tert-butyl), 1.36 (3H, m, CH 3 -alanine), 1.00 (3H, m, CH 3 2'-guanosine). Example 9 15 Synthesis of 2', 3'-0,O-lsopropyidene-p-2'-methyl-guanosine 5'-O-[phenyl(benzoxy Lalaninyl)] phosphate O O o NH NN N

NH

2 00 WO 2008/062206 PCT/GB2007/004480 31 Prepared according to Standard Procedure C2, from 2', 3'-0,0-isopropylidene-#-2' methyl-guanosine (120 mg, 0.355 mmol), t BuMgCl (1.0 ml, IM solution in THF, 1.07 mmol) and phenyl(benzoxy-L-alaninyl) phosphorochloridate (1.0 ml of solution IM in THF, 1.07 mmol). The crude was purified by column chromatography, using as eluent 5 CHCI 3 /MeOH (9:1) followed by semi-preparative HPLC. The obtained pure product was a white solid (40 mg, 0.061 mmol, 17%). 6p (dv-CH 3 0H): 4.63, 4.37; 8 H (drCH 3 0H): 7.85 (1H, d, H8-guanosine, J'= 5.7 Hz), 7.36 7.34 (5H, m, 2 CH-phenyl, 3 CH-benzyl), 7.33-7.26 (5H, mn, 2 CH-benzyl, 3 CH-phenyl), 6.02 (1H, d, H1'-guanosine, J= 11.4 Hz), 5.16 (21, s, CH 2 -benzyl), 4.67 (1H, d, H3' 10 guanosine, J= 1.1 Hz), 4.54-4.43 (1H, m, H4'-guanosine), 4.31 (2H, H5'guanosine), 4.10 (IH, m, CHa), 1.61 (3H, s, CH 3 -isopropylidine), 1.53 (3H, s, CH 3 -isopropylidine), 1.39 (3H, d, CH 3 -alanine, J= 8.4 Hz), 1.00 (3H, s, CH 3 -2'-guanosine). Synthesis of -2'-methyl-guanosine 5'-0-[phenyl (benzoxy-L-alaninyl)] phosphate 15 (CHC9) CHC9 0 0N %po.NHN

YNH

2 OH OH Prepared according to Standard Procedure C4, from 2', 3'-O,0-isopropylidene-p-2' methyl-guanosine 5'-0-[pheny(benzoxy-L-alaninyl)) phosphate (40 mg, 0.061 mmol), 20 and 10 ml of a solution 60% of CH 3 COOH in water at 90* C for 15 hours. The crude was purified by column chromatography, using as eluent for the first CHCl 3 /MeOH (85:5) followed by a semi-preparative HPLC. The obtained pure product was a white solid (15 mg, 0.024 mmol, 40%). Bp (d4.CH 3 0II): 4.27, 4.10; 8H (d 4 rCH 3 0H): 7.92 (1H, d, H8-guanosine, J= 8.3 Hz), 7.37 25 7.29 (5H, m, 2 CH-phenyl, 3 CH-benzyl), 7.25-7.18 (51, m, 2 CH-benzyl, 3 CH-phenyl), WO 2008/062206 PCT/GB2007/004480 32 5.96 (1H, d, H1'-guanosine, J= 2.3 Hz), 5.15 (2H, s, CH 2 -benzyl), 4.43-4.35 (2H, m, H3' guanosine, H4'-guanosine), 4.33-4.28 (1H, m, H5'-guanosine), 4.24-4.19 (1H, m, H5' guanosine), 4.08-3.93 (111, m, CHg), 1.35 (311, m, CH 3 -alanine), 1.24 (31, s, CH 3 -2' guanosine). 5 Example 10 Synthesis of 2', 3'-O,0-isopropylidene-fp-2'-methyl-guanosine 5'-0-[phenyl(methoxy L-alaninyl)) phosphate 0 NH PH N

NH

2 10 Prepared according to Standard Procedure C2, from 2', 3'-O,O-isopropylidene-P-2' methyl-guanosine (130 mg, 0.385 mmol), 'BuMgC1 (0.96 ml, IM solution in THF, 0.96 mmol) and g-naphthyl(methoxy-L-alaninyl) phosphorochloridate (0.96 ml of solution IM in THF, 0.96 mmol). The crude was purified by column chromatography, using as fluent 15 CHC 3 /MeOH (97:3). The obtained pure product was a white solid (26 mg, 0.041 mmol, 11%). 8p (d 4

CH

3 0H): 4.51, 4.45; 8 u (drCH 3 0H): 8.21 (1H, d, H8-guanosine, J= 7.5 Hz), 7.91 7.89 (1H, m, CH-naphthyl), 7.73 (1H, m, CH-naphthyl), 7.58-7.53 (4H, m, 4 CH naphthyl), 7.48-7.45 (IH, m, CH-naphthyl), 6.09 (1H, d, H1'-guanosine, J= 7.4 Hz), 4.63 20 (1H, d, H3'-guanosine, J= 3.0 Hz), 4.57-4.53 (2H, m, H4'-guanosine), 4.43-4.41 (2H, m, H5'guanosine), 4.12-4.05 (1H, m, CHg), 3.62 (3H, d, CH 3 -methyl, J= 10.1 Hz), 1.59 (3H, d, CH 3 -isopropylidine, J= 7.9 Hz), 1.40 (3H, d, CH 3 -alanine, .= 3.4 Hz), 1.35 (3H, d, CH3 isopropylidine, J 7.2 Hz), 1.05 (3H, d, CH 3 -2'-guanosine, J= 7.0 Hz). 25 Synthesis of p-2'-methyl-guanosine 5'-0-[g-naphthyl(methoxy-L-alaninyl)] phosphate (CHC10) WO 2008/062206 PCT/GB2007/004480 33 Me O O NH O0 OH OH Prepared according to Standard Procedure C4, from 2', 3'-0,0-isopropylidene-fp-2' methyl-guanosine 5'-0-[a-naphthyl(methoxy-L-alaninyl)) phosphate (26 mg, 0.041 5 mmol), and 10 ml of a solution 60% of CH 3 C00H in water at 90' C for 15 hours. The crude was purified by column chromatography, using as eluent for the first CHCl 3 /MeOH (92:8). The obtained pure product was a white solid (4.1 mg, 0.007 mmol, 17%). 8 p (d4CH 3 0H): 4.35, 4.26; 8H (d 4

-CH

3 0H): 8.20 (1H, d, H8-guanosine, J= 5.8 Hz), 7.91 7.87 (2H, m, CH-naphthyl), 7.70 (1H, m, CH-naphthyl), 7.58-7.52 (3H, m, 3 CH 10 naphthyl), 7.50-7.41 (1H, m, CH-naphthyl), 5.93 (1H, s, H1'-guanosine), 4.58-4.56 (2H, m, H3'-guanosine, H4'-guanosine), 4.29-4.21 (2H, m, H5'guanosine), 4.06-4.03 (1H, m, CHa), 3.56 (3H, d, CHrmethyl, J= 1.7 Hz), 1.31 (3H, d, CH 3 -alanine, J= 7.4 Hz), 1.00 (3H, d, CH 3 -2'-guanosine, J= 12.4 Hz). 15 Example 11 Synthesis of 2', 3'-0,0-isopropylidene-fJ-2'-methyl-guanosine 5'-0-[phenyl(methoxy L-alaninyl)] phosphate 0,Me 0 0 N N O OH

NH

20 Prepared according to Standard Procedure C2, from 2', 3'-0,0-isopropylidene-#-2' methyl-guanosine (140 mg, 0.415 mmol), 'BuMgC1 (1.04 ml, IM solution in THF, 1.04 mmol) and phenyl(methoxy-L-alaninyl) phosphorochloridate (1.04 nil of solution 1M in WO 2008/062206 PCT/GB2007/004480 34 THF, 1.04 mmol). The crude was purified by column chromatography, using as eluent CHCla/MeOH (97:3). The obtained pure product was a white solid (21 mg, 0.036 mmol, 9%). 8p (drCH 3 OH): 4.09, 3.91; 8n (d 4

-CH

3 0H): 7.88, 7.80 (1H, d, HS-guanosine), 7.41-7.35 5 (2H, m, CH-phenyl), 7.30-7.20 (3H, m, 3 CH-phenyl), 6.14 (1H, d, H1'-guanosine, J= 11.8 Hz), 4.69 (IH, d, H3'-guanosine, J= 2.9 Hz), 4.49-4.39 (3H, m, H4'-guanosine, H5'guanosine), 4.04-3.99 (1H, m, CHa), 3.70 (3H, d, CH 3 -methyl, J= 12.7 Hz), 1.63 (3H, d, CH 3 -isopropylidine, .J= 2.3 Hz), 1.44 (3H, d, CH 3 -alanine, .J 3.1 Hz), 1.41 (3H, d, CH 3 isopropylidine, J= 6.8 Hz), 1.10 (3H, d, CH 3 -2'-guanosine, J= 6.5 Hz). 10 Synthesis of &-2'-methyl-guanosine 5'-O-[phenyl(methoxy-L-alaninyl)] phosphate (CHCl1). M e pT N N OH OH 15 Prepared according to Standard Procedure C4, from 2', 3'-0,0-isopropylidene-p-2' methyl-guanosine 5'-O-[phenyl(methoxy-L-alaninyl)] phosphate (21 mg, 0.036 mmol), and 10 ml of a solution 60% of CH 3 COOH in water at 900 C for 15 hours. The crude was purified by column chromatography, using as eluent for the first CHC1s/MeOH (92:8). The obtained pure product was a white solid (7.0 mg, 0.013 mmol, 36%). 20 8p (dt-CH 3 0H): 4.15, 3.90; 8n (drCH 3 0H): 8.96 (1H, br, H8-guanosine), 7.40-7.35 (2H, In, CH-phenyl), 7.29-7.20 (3H, m, 3 CH-phenyl), 6.08 (1H, d, H1'-guanosine, J- 8.5 Hz), 4.55-4.49 (2H, m, H3'-guanosine, H4'-guanosine), 4.26 (IH, m, H5'guanosine), 4.17-4.11 (IH, m, H5'-guanosine), 4.00-3.97 (1H, m, CHa), 3.73 (3H, d, CH 3 -methyl, J= 11.1 Hz), 1.36 (3H, d, CH 3 -alanine, J- 7.1 Hz), 1.41 (3H, d, CH 3 -isopropylidine, J= 6.8 Hz), 1.14 25 (3H, d, CH 3 -2'-guanosine, J 4.9 Hz).

WO 2008/062206 PCT/GB2007/004480 35 Each of compounds CHCl to CHC9, as prepared according to Examples 1 to 11, respectively, was tested for its potency with respect to HCV. The anti-HCV assays employed were: 5 Anti-HCV assay in Huh 7 cells. Huh 7 cells containing subgenomic HCV replicons 1 389 1uc-ubi-neo/NS3-3'/5.l (Huh 5-2) or 1 377 /NS3-3'/wt (Huh 9-13) have been described (Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 10 285:110-113. Lohmann V, Korner F, Dobierzewska A, Bartenschlager R. (2001) Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol. 75:1437 1449.). Cells were grown in Dulbecco's modified Eagle's Medium (DMEM; Gibco, Merelbeke, Belgium) supplemented with 10% heat-inactivated fetal bovine serum (FCS) (Integro, Zaandam, The Netherlands), lx non-essential amino acids (Gibco), 100 IU/ml 15 penicillin (Gibco), 100 pg/ml streptomycin (Gibco) and 250 pg/ml Geneticin (G418, Gibco) for Huh 5-2 cells, 1000 pg/ml G418 for Huh 9-13 cells Anti-HCV assay in Hub 5-2 cells. Huh 5-2 cells were seeded at a density of 5 x 10' per well in a tissue culture treated white 96-well view plate (Packard, Canberra, Canada) in 20 complete DMEM supplemented with 250 pg/ml G418. Following incubation for 24 h at 37*C (5% CO 2 ) medium was removed and serial dilutions in complete DMEM (without 0418) of the test compounds were added in a total volume of 100 Pl. After 4 days of incubation at 37*C, cell culture medium was removed and luciferase activity was determined using the Steady-Glo luciferase assay system (Promega, Leiden, The 25 Netherlands); the luciferase signal was measured using a Luminoskan Ascent (Thermo, Vantaa, Finland). The 50% effective concentration (ECso) was defined as the concentration of compound that reduced the luciferase signal by 50%. Anti-HCV assay in Hub 9-13 cells. 30 Huh 9-13 cells were seeded at a density of 5 x 103 cells per well in 96-well cell culture plates in complete DMEM supplemented with 1000 pg/ml G418. Following incubation for 24 h at 37*C cell culture medium was removed and serial dilutions of the test compounds in complete DMEM without G418 were added in a total volume of 100 pl. After 4 days of WO 2008/062206 PCT/GB2007/004480 36 incubation at 37*C, cell culture fluid was removed and monolayers were washed once with phosphate-buffered saline. Cells were lysed in 350 pl RLT buffer (Qiagen, Venlo, Ie Netherlands) according to the Manufacturer's instruction. Lysates were stored at -80 0 C until further use. 5 RT-qPCR. A 25 pL RT-qPCR reaction contained 12.5 pl 2x reaction buffer (Eurogentec, Seraing, Belgium), 6.3 pt H 2 0, 5 pl total cellular RNA extract and in the case of Huh 9-13 and HuH6 samples 300 nmol/L neo-forward primer [5'-CCG GCT ACC TGC CCA TTC 3'], 300 nmol/L neo-reverse primer [5'-CCA GAT CAT CCT GAT COA CAA G-3'], 300 10 nmol/L neo-probe [5'-FAM-ACA TCG CAT CGA GCG AGC ACG TAC-TAIRA-3'] or for Huh-mono samples 300 nmol/L UTR-forward primer [5'-ACG CAG AAA GCG TCT AGC CAT GGC GTT AGT-3'], 300 nmol/L UTR-reverse primer [5'-TCC CGG GGC ACT CGC AAG CAC CCT ATC AGG-3'], 300 nmol/L UTR-probe [5'-FAM-TGG TCT GCG GAA CCG GTG AGT ACA CC-TAMRA-3']. The RT step was performed at 48*C 15 for 30 minutes, 15 minutes at 95"C and subsequent PCR amplification of 40 cycles of denaturation at 94*C for 20 seconds and annealing and extension at 60*C for 1 minute in an ABI 7000 sequence detector. The 50% effective concentration (ECso) was defined as the concentration of compound that reduced replicon RNA content by 50%. 20 The results in terms of HCV ECs/pM and CCSo/pM are given in Table I below. In Table I: A refers to 9-linked adenine, G refers to 9-linked guanine, Nap refers to l-naphthyl ( 25 CIOH 9 ), Ph refers to phenyl (-C 6

H

5 ), Et refers to ethyl (CH 3

CH

2 -), Bn refers to benzyl (C6H 5

CH

2 -), t-Bu refers to tertiary butyl ((CH 3

)

3 C-) and Me refers to methyl (CH 3 -). 30 WO 2008/062206 PCT/GB2007/004480 37 Table I Compound Base Ar R 3 HCV HCV CCso/sM Huh 5-2 Huh 9-13 ECsO/pM ECso/pM 0.14 29 CHC1 A - - 0.05 >33 0.13 >33 CHC2 A Nap Et 0.12 >50 CHC3 A Nap Bn 0.16 44 CHC4 A Nap t-Bu 2.36 >50 3 1.5 >50 CHC 0 5 >50 0.08 >50 0.032 >50 CHC6 a Nap Bn 0.11 0.06 >50 0.13 >50 0.044 >50 0.15 >50 CHC7 0 Nap Et 0.2 >50 0.16 >50 CHC8 G Nap t-Bu >50 >50 CHC9 G Ph Bn 36 4.1 >50 0.87 >50 CHCIO G Ph Me 0.88 >50 0.14 >50 CHC11 G Nap me 0.063 >50 The data in Table I show that each of the compounds CHC6 and CHC7 embodying the 5 present invention exhibits greater potency with respect to HCV than compound CHC5 which corresponds to the free nucleoside 9-linked guanine. A comparison of the data in Table I with respect to each of compounds CHC6 and CHC9, and with respect to each of compounds CHC1O and CHCI 1, shows that the enhanced 10 potency with respect to HCV is attributable to the presence in compounds CHC6 and CHC11, respectively, of Ar being 1-naphthyl.

38 Table II below sets out the structures of the presently exemplified compounds CHCI to CHCI 1 in terms of formula I above, with in each case Z=H and Q = 0. Table 11 Compound X Y T" V T Ar R, R 2

R

3

R

4 CHCL NH 2 H H OH H - - -' CHC2 NH 2 H H OH H CH 7 CH, H CH 3

CH

2 H CHC3 NH 2 H H OH H C 1

OH

7 CH, H C 6

HCH

2 H CHC4 NH 2 H H OH H CioH 7

CH

3 H t-C 4 Hq H CHC5 =0 NH2 H OH H - - - CHC6 =0 NH2 H OH H CtoH CH 3 H CH 5

CH

2 H CHC7 -0 NH 2 H OH H CIoH 7

CH

3 H CH 3

CH

2 H CHCS =0 NH 2 H OH H CioH, CH, H t-C4H, H CHC9 =0 NH 2 H OH H C 6

H

5

CH

3 H C5H5CH 2 H CHCIO =0 NH 2 H OH H CHs CH, H CH, 3 CHC11 =0 NH 2 H OH H CIOH, CH, H CH 3 H 5 Where Ar is CIOH 7 , it is 1-naphthyl. Where X is NH 2 , n is 0. Where X is =0, n is 1. 10 Each of compounds CHC 1, CHC5, CHC9 and CHC 10 is a comparative compound. Compound CHC 1 corresponds to the non-phosphoramidated, free nucleoside 9-linked adenine. 15 Compound CHC5 corresponds to the non-phosphoramidated, free nucleoside 9-linked guanine. Throughout the description and claims of the specification, the word "comprise" and variations of the word, such as "comprising" and "comprises", is not intended to exclude other additives, components, 20 integers or steps. A reference herein to a patent document or other matter which is given as prior art is not to be taken as an admission or a suggestion that that document or matter was, known or that the information it contains was part of the common general knowledge as at the priority date of any of the claims. C:poword\oQ ment1.doc

Claims (25)

1. 2. A compound according to claim 1 wherein T is selected from the group consisting of hydrogen (H-), fluoro (F-), methyl (CH 3 -) and ethyl (CH 3 CH 2 -).
2. 3. A compound according to any one of the preceding claims wherein V is selected from the group consisting of hydrogen (H-), fluoro (F-) and OT' wherein T' is hydrogen (H-) or methyl (CH 3 -).
3. 4. A compound according to any one of the preceding claims wherein T" is H.
4. 5. A compound according to any one of the preceding claims wherein T is H, V is OH and T" is H.
5. 6. A compound according to any one of the preceding claims wherein n is 1, X is =0 and Y is NH 2 .
6. 7. A compound according to claim 6 wherein Z is H.
7. 8. A compound according to any one of claims 1 to 5 wherein n is 0, a double bond exists between position 3 and position 4, X is selected from the group consisting of NH 2 , F, Cl and NR 5 R 6 where one of R 5 and R 6 is C 1 . 6 alkyl.
8. 9. A compound according to claim 8 where X is NH 2 , Y is H and Z is H.
9. 10. A compound according to any one of the preceding claims where Q is 0.
10. 11. A compound according to any one of the preceding claims wherein R 3 is alkyl.
11. 12. A compound according to claim I1 wherein R 3 is selected from the group consisting of methyl, ethyl, 2-propyl, n-propyl, cyclohexyl, 2-butyl and benzyl.
12. 13. A compound according to any one of the preceding claims wherein R 4 is H. C:\powordSPEC-949383.dOCx 42
13. 14. A compound according to any one of the preceding claims wherein R, and R 2 are selected such that the moiety -N-CRIR 2 -COO- corresponds to that of a natural amino acid.
14. 15. A compound according to any one of the preceding claims wherein each of R, and R 2 is independently selected from methyl (-CH 3 ) and H.
15. 16. A compound according to claim 15 wherein one of Ri and R 2 is methyl and one of R, and R 2 is H such that the C atom bearing R, and R 2 has chirality L as in natural alanine.
16. 17. A compound according to any one of the preceding claims comprising the diastereoisomer Rp, the diastereoisomer Sp or a mixture of the diastereoisomers R, and Sp.
17. 18. A compound according to any one of claims I to 17 for use in a method of treatment.
18. 19. A compound according to claim 18 for use in the prophylaxis or treatment of a viral infection.
19. 20. A compound according to claim 17 for use in the prophylaxis or treatment of hepatitis C virus.
20. 21. A pharmaceutical composition comprising a compound according to any one of claims 1 to 17 in combination with a pharmaceutically acceptable carrier, diluent or excipient.
21. 22. A method of preparing a pharmaceutical composition comprising the step of combining a compound according to any one of claims 1 to 17 with a pharmaceutically acceptable excipient, carrier or diluent.
22. 23. A method of treatment using a compound according to any one of claims 1-17.
23. 24. A method according to claim 23 wherein said treatment is the prophylaxis or treatment of a viral infection. C:Ipot\wOrd\SPEC-949383.docx 43
24. 25. A method of treatment according to claim 24 wherein said treatment is the prophylaxis or treatment of Hepatitis C virus.
25. 26. A compound according to claim 1, substantially as hereinbefore described with reference to any of the examples and/or figures. C:\pofwd\PEC-949383 d ox